JY
BCLI

Jeff Yass’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jeff Yass’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,533
Closed -$5.3K – 12175
2024
Q3 		$5.3K Sell
1,533
-27
-2% -$127 ﹤0.01% 11754
2024
Q2 		$7.96K Buy
+1,560
New +$11.7K ﹤0.01% 11797
2024
Q1 		– Sell
-3,287
Closed -$13.3K – 12167
2023
Q4 		$13.3K Buy
3,287
+1,647
+100% +$4.94K ﹤0.01% 12036
2023
Q3 		$4.92K Sell
1,640
-27,747
-94% -$631K ﹤0.01% 11791
2023
Q2 		$908K Buy
29,387
+15,447
+111% +$640K ﹤0.01% 6906
2023
Q1 		$690K Buy
13,940
+12,733
+1,055% +$369K ﹤0.01% 7758
2022
Q4 		$29.7K Sell
1,207
-2,100
-64% -$78.5K ﹤0.01% 11624
2022
Q3 		$219K Sell
3,307
-2,213
-40% -$111K ﹤0.01% 10596
2022
Q2 		$229K Sell
5,520
-5,527
-50% -$249K ﹤0.01% 10281
2022
Q1 		$557K Sell
11,047
-9,146
-45% -$449K ﹤0.01% 8706
2021
Q4 		$1.21M Sell
20,193
-3,907
-16% -$192K ﹤0.01% 6770
2021
Q3 		$1.19M Sell
24,100
-1,727
-7% -$90.9K ﹤0.01% 7085
2021
Q2 		$1.47M Buy
25,827
+294
+1% +$15.7K ﹤0.01% 6694
2021
Q1 		$1.47M Sell
25,533
-4,974
-16% -$376K ﹤0.01% 6696
2020
Q4 		$2.07M Buy
30,507
+15,720
+106% +$2.14M ﹤0.01% 5020
2020
Q3 		$3.75M Buy
14,787
+3,240
+28% +$664K ﹤0.01% 3500
2020
Q2 		$1.94M Buy
11,547
+2,407
+26% +$260K ﹤0.01% 4559
2020
Q1 		$636K Buy
9,140
+7,433
+435% +$580K ﹤0.01% 6406
2019
Q4 		$110K Sell
1,707
-2,240
-57% -$130K ﹤0.01% 9096
2019
Q3 		$231K Sell
3,947
-2,900
-42% -$171K ﹤0.01% 8820
2019
Q2 		$406K Buy
6,847
+2,354
+52% +$137K ﹤0.01% 7706
2019
Q1 		$293K Buy
+4,493
New +$256K ﹤0.01% 7253
2018
Q1 		– Sell
-2,247
Closed -$132K – 9304
2017
Q4 		$132K Sell
2,247
-306
-12% -$18.3K ﹤0.01% 8571
2017
Q3 		$158K Buy
+2,553
New +$165K ﹤0.01% 8162
2016
Q4 		– Sell
-2,733
Closed -$98K – 9558
2016
Q3 		$98K Buy
+2,733
New +$102K ﹤0.01% 7945
2015
Q4 		– Sell
-880
Closed -$30K – 9405
2015
Q3 		$30K Buy
+880
New +$41.4K ﹤0.01% 9448

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's BCLI Position: Q2 2024 in Review

Jeff Yass sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 1,770 shares — an estimated $13.3K sold.

Jeff Yass first reported a position in BCLI in Q1 2016 and held it in 21 quarters. The position peaked at $1.68M in Q4 2020. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Jeff Yass reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Jeff Yass sold 1,770 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $13.3K.
  • Jeff Yass first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 21 quarters.
  • Jeff Yass's BRAINSTORM CELL THERAPUTC position peaked at $1.68M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.